{
    "clinical_study": {
        "@rank": "116156", 
        "arm_group": [
            {
                "arm_group_label": "MEDI8897", 
                "arm_group_type": "Experimental", 
                "description": "Anti-RSV monoclonal antibody with an extended half-life."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Solution containing no active ingredients"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an\n      extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to\n      placebo when administered to healthy adult subjects."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Syncytial Virus", 
        "detailed_description": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to\n      evaluate the safety, tolerability and pharmacokinetics of MEDI8897 compared to placebo when\n      administered to healthy adult subjects. Approximately 72 subjects will be entered to receive\n      treatment across 5 fixed dose cohorts at 1 site.  Investigational product will be delivered\n      intravenously (IV) to 3 cohorts and intramuscularly (IM) to 2 cohorts. A total of 4\n      different dose levels of investigational product will be evaluated across the 5 cohorts.\n      Subjects will be followed for approximately 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Age 18 through 49 years and in good health by history, physical exam, and labs\n\n          -  Weight \u2265 45 kg and \u2264 110 kg at screening\n\n          -  Written informed consent prior to performing any protocol related procedures,\n             including screening evaluations\n\n          -  Ability to complete the follow-up period of 360 days\n\n        Key Exclusion Criteria:\n\n          -  Acute illness including fever \u2265 99.5\u00b0F on day of dosing\n\n          -  Any drug therapy within 7 days prior to Day 1 (except contraceptives)\n\n          -  Receipt of any investigational drug therapy within 120 days prior to investigational\n             product dosing through 360 days after investigational product dosing\n\n          -  Previous receipt of a monoclonal antibody (mAb)\n\n          -  Pregnant or nursing mother\n\n          -  Concurrent enrollment in another interventional study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114268", 
            "org_study_id": "D5290C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "MEDI8897", 
                "description": "Dose 1 - intramuscular (IM) delivery; Dose 2 - intravenous (IV) and intramuscular (IM) delivery; Dose 3 - intravenous (IV) delivery; Dose 4 - intravenous (IV) delivery", 
                "intervention_name": "MEDI8897", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Solution containing no active ingredients", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Respiratory Syncytial Virus, RSV", 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults", 
        "other_outcome": [
            {
                "measure": "Anti-RSV neutralization concentrations in serum", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }, 
            {
                "measure": "Anti-RSV neutralization concentrations in nasal wash", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Assessment of RSV neutralizing activity of MEDI8897", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Assessment of MEDI8897 concentrations in nasal wash", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }
        ], 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "MedImmune Contact"
        }, 
        "overall_official": [
            {
                "affiliation": "MedImmune LLC", 
                "last_name": "M. Pamela Griffin, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Study Site", 
                "last_name": "Martin Kankam, MD, PhD, MPH", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Occurrence of adverse events, serious adverse events, adverse events of special interest, and new onset chronic disease.", 
                "measure": "Safety and tolerability of MEDI8897", 
                "safety_issue": "Yes", 
                "time_frame": "360 days"
            }, 
            {
                "description": "Clinical laboratory assessments (ie, serum chemistry, hematology, and urinalysis)", 
                "measure": "Safety and tolerability of MEDI8897", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This variable will be estimated for MEDI8897 in the IV and IM cohorts where the data allow.", 
                "measure": "Pharmacokinetics of MEDI8897 in serum: terminal-phase elimination (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }, 
            {
                "description": "This variable will be estimated for MEDI8897 in the IV cohorts where the data allow.", 
                "measure": "Pharmacokinetics of MEDI8897 in serum: systemic clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }, 
            {
                "description": "This variable will be estimated for MEDI8897 in the IM cohorts where the data allow.", 
                "measure": "Pharmacokinetics of MEDI8897 in serum: extravascular systemic clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }, 
            {
                "description": "This variable will be estimated for MEDI8897 in the IM cohorts where the data allow.", 
                "measure": "Pharmacokinetics of MEDI8897 in serum: bioavailability (F)", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }, 
            {
                "measure": "Incidence of anti-drug antibody to MEDI8897 in serum", 
                "safety_issue": "No", 
                "time_frame": "360 days"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}